Compare INSG & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | PLRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 63.2M |
| IPO Year | 2000 | 2020 |
| Metric | INSG | PLRX |
|---|---|---|
| Price | $4.33 | $0.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.67 | $2.67 |
| AVG Volume (30 Days) | 331.9K | ★ 373.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $313,832,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.21 | N/A |
| P/E Ratio | $35.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.58 | $0.97 |
| 52 Week High | $21.90 | $1.95 |
| Indicator | INSG | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 34.84 |
| Support Level | $3.96 | N/A |
| Resistance Level | $4.61 | $1.37 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 57.10 | 11.39 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.